Furthermore, lomitapide reduced tumor cell proliferation and significantly prolonged survival in at least one in vivo GBM model, suggesting that targeting lipid metabolism may represent a promising therapeutic strategy for both NF1-mutant and NF1 wild-type GBMs. The gene discussed is NF1; the disease is glioblastoma.